UPDATE: Berenberg Starts BioXcel Therapeutics (BTAI) at Buy

April 9, 2021 6:45 AM EDT
Get Alerts BTAI Hot Sheet
Price: $25.49 -1.77%

Rating Summary:
    11 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 13 | New: 31
Trade Now! 
Join SI Premium – FREE
(Updated - April 9, 2021 7:04 AM EDT)

Berenberg analyst Anita Dushyanth initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Buy rating and a price target of $75.00.

The analyst commented, "BioXcel Therapeutics has a proprietary EvolverAI platform technology that significantly reduces drug development timelines. The drug candidates address large markets in neuropsychiatry and immune-oncology that have high unmet medical needs. The company became public in March 2018 at USD11 and the price has since appreciated by more than 227% (USD36), versus XBI, which is up by 37%. We believe there is significant upside potential both in the near and long term for this stock."

For an analyst ratings summary and ratings history on BioXcel Therapeutics click here. For more ratings news on BioXcel Therapeutics click here.

Shares of BioXcel Therapeutics closed at $36.20 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage